Tenofovir Disoproxil Fumarate for HIV

N/A

Waitlist Available

Research Sponsored by Gilead Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients who are at least 18 years old

Patients who have failed treatment with at least 2 protease inhibitors (PIs) or at least 1 PI plus a nonnucleoside reverse transcriptase inhibitor (NNRTI)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial makes an unapproved drug available to people with HIV who have few treatment options left and whose disease may worsen.

Who is the study for?

This trial is for HIV-positive adults with a viral load over 10,000 copies/ml and CD4 count of 100 cells/mm3 or lower, or up to 200 cells/mm3 if they had an AIDS-related infection recently. They must have failed treatments with at least two protease inhibitors or one plus a nonnucleoside reverse transcriptase inhibitor and can't be treated effectively with approved anti-HIV drugs.Check my eligibility

What is being tested?

The study provides access to tenofovir disoproxil fumarate (DF) for patients who haven't succeeded with other anti-HIV drug combinations. It aims to offer this medication before it's commercially available to those running out of treatment options due to resistance.See study design

What are the potential side effects?

While the specific side effects are not listed here, tenofovir DF may cause kidney problems; hence individuals taking medications that affect the kidneys were excluded from the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have tried at least 2 PIs or 1 PI and 1 NNRTI without success.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor

1,084 Previous Clinical Trials

848,479 Total Patients Enrolled

Media Library

Tenofovir Disoproxil Fumarate (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT00011089 — N/A

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Tenofovir Disoproxil Fumarate Highlights & Side Effects. Trial Name: NCT00011089 — N/A

Tenofovir Disoproxil Fumarate (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00011089 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there available spots for participants in this trial?

"The trial, which was first posted on February 1st 2001 and updated lastly on June 23rd 2005, is not actively enrolling participants at this moment. However, clinicaltrials.gov has noted that 484 other studies are presently recruiting patients to take part in their trials."

Answered by AI